Departments of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA.
Am J Clin Oncol. 2013 Apr;36(2):132-42. doi: 10.1097/COC.0b013e3182438ddf.
The survival of patients with renal cell carcinoma (RCC) has improved in recent years. However, data on the risk of developing a second cancer after a diagnosis of RCC is limited. We used the data available in the Surveillance Epidemiology and End Results (SEER) database to estimate the risk of second metachronous primary cancers in patients diagnosed with RCC between 1973 and 2006. Furthermore, we also investigated the effect of the second primary cancers (SPCs) on the survival of RCC patients.
A total of 3795 cases of SPCs were registered in the SEER between 1973 and 2006. The ratio of observed/expected number of SPCs in RCC was 1.18, which was significantly greater than expected. Solid tumors comprised 90% of all second malignancies in RCC patients, with the most second cancers reported in the prostate gland and the digestive and respiratory systems. The overall risk of second primaries was highest in patients aged over 30 years at the time of diagnosis. The site-specific risk of second cancers varied with the age at diagnosis, sex, race of the patient, size of the primary renal tumor, and history of radiation therapy. Patients with second primaries had a significantly longer overall survival than those without second malignancies. An interval of <1 year between the diagnosis of RCC and the second primary was the strongest predictor of poor overall survival in RCC patients with a second malignancy.
Patients with RCC are at a significantly higher risk of developing a second malignancy, suggesting the need for careful surveillance for their early detection and management.
近年来,肾细胞癌(RCC)患者的生存率有所提高。然而,关于 RCC 诊断后发生第二原发癌的风险数据有限。我们利用监测、流行病学和最终结果(SEER)数据库中的数据,估计了 1973 年至 2006 年间诊断为 RCC 的患者发生第二原发癌(SPC)的风险。此外,我们还研究了第二原发癌(SPC)对 RCC 患者生存的影响。
1973 年至 2006 年间,SEER 共登记了 3795 例 SPC。RCC 观察到/预期 SPC 数的比值为 1.18,明显高于预期。实体瘤占所有 RCC 患者第二恶性肿瘤的 90%,报告的第二癌症中最常见的是前列腺癌和消化系统及呼吸系统癌症。诊断时年龄超过 30 岁的患者第二原发癌的总体风险最高。第二癌症的部位特异性风险与诊断时的年龄、性别、患者种族、原发肾肿瘤大小以及放疗史有关。有第二原发癌的患者总生存率明显长于无第二恶性肿瘤的患者。RCC 诊断后与第二原发癌之间的间隔<1 年是预测伴有第二恶性肿瘤的 RCC 患者总体生存率较差的最强预测因素。
RCC 患者发生第二恶性肿瘤的风险显著增加,这表明需要仔细监测以早期发现和管理。